Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13400272 | 0.84 | ALDH1A1 (0.32) | ALDH1A1SMN1; SMN2MAPK1TDP1SLC6A2 | |
| SCHEMBL13432805 | 0.82 | PNMT (0.40) | ALDH1A1SMN1; SMN2MAPK1TDP1LMNA | |
| SCHEMBL1710472 | 0.81 | ALDH1A1 (0.34) | ALDH1A1SMN1; SMN2MAPK1TDP1LMNA | |
| SCHEMBL1722655 | 0.80 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2MAPK1TDP1SLC6A2 | |
| SCHEMBL1724735 | 0.79 | L3MBTL1 (0.36) | ALDH1A1SMN1; SMN2MAPK1TDP1LMNA | |
| SCHEMBL1710625 | 0.76 | AR (0.41) | — | |
| SCHEMBL1710722 | 0.75 | SMN1; SMN2 (0.35) | ALDH1A1SMN1; SMN2MAPK1TDP1LMNA | |
| SCHEMBL13400235 | 0.75 | AR (0.41) | SMN1; SMN2MAPK1LMNA | |
| SCHEMBL10237228 | 0.75 | MEN1 (0.36) | SLC6A2SLC6A4 | |
| SCHEMBL2151253 | 0.75 | P2RX7 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344451-A2 | SULFUR-LINKED COMPOUNDS FOR TREATING OPTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2010028088-A2 | SULFUR-LINKED COMPOUNDS FOR TREATING OPTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, MPST, CLN6 | ALDH1A1 314/4885SMN1; SMN2 129/4885MAPK1 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.